Dyadic International (DYAI) vs TScan Therapeutics (TCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Dyadic International (DYAI) has outperformed TScan Therapeutics (TCRX) over the past year, losing 60.7% versus a loss of 89.0%. Over five years, DYAI leads with a -90.8% price change compared with -96.5% for TCRX. Dyadic International is the larger company by market cap ($17.8 million vs $16.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | TCRX |
|---|---|---|
| Share price | $0.4441 | $0.238 |
| Market cap | $17.79M | $16.13M |
| 1-day change | -0.07% | +4.29% |
| YTD return | -52.76% | -76.20% |
| 1-year return | -60.70% | -89.03% |
| 5-year return | -90.84% | -96.47% |
| EPS (TTM) | $-0.23 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $2.57 |
| 52-week low | $0.34 | $0.224 |
| Distance from 52-week high | -72.24% | -90.74% |
| Analyst consensus | none | hold |
| Avg. price target upside | +1138.46% | +320.17% |
| Average volume | 203.60K | 784.00K |
| Shares outstanding | 40.06M | 63.50M |
| Employees | 5 | 138 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed TCRX by 28.3 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About TScan Therapeutics
TCRX stock →TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 138 employees
DYAI vs TCRX FAQ
Which is bigger, Dyadic International or TScan Therapeutics?
Dyadic International (DYAI) is larger, with a market capitalization of $17.79M compared with $16.13M for TScan Therapeutics (TCRX).
Which stock has performed better over the past year, DYAI or TCRX?
DYAI returned -60.70% over the past 12 months, compared with -89.03% for TCRX (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and TScan Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.